Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding shareholding changes.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific share transaction rather than a financial performance report.
Material Changes
The filing details an increase in the holding of Ordinary shares by a connected person, Ms. S Dexter, following the re-investment of a dividend paid on January 5, 2012, and the purchase of shares on January 6, 2012.
- Transaction Date: January 6, 2012
- Share Price: 1497.92 pence per share
- Shares Acquired: 129 Ordinary shares
- Related Director/PDMR: Dr. P J T Vallance
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the share transaction in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Key Facts for Investor Verification
- Verify the total shareholding of Ms. S Dexter post-transaction to assess concentration relative to the company's total float.
- Confirm the dividend reinvestment plan details applicable to the January 5, 2012 payment.
- Check subsequent filings to ensure no further undisclosed transactions occurred for the connected persons listed.